在早期试验中,HBI-3000和AP31969显示出作为心房动的更安全的治疗方法的前景. HBI-3000 and AP31969 show promise in early trials as safer treatments for atrial fibrillation.

HHOYABIO报告说,HBI-3000第1阶段的成果是积极的,HBI-3000是用于急性性纤维化的静脉注射药物,表明这种药物是精心制造的,有效抑制了关键心脏离子渠道,没有造成像QT延长这样的危险的副作用。 HUYABIO reports positive Phase 1 results for HBI-3000, an intravenous drug for acute atrial fibrillation, showing it was well-tolerated and effectively inhibited key heart ion channels without causing dangerous side effects like QT prolongation. 艾西森制药公司已经开始对口服药物AP31969进行第二阶段试验,试验其在欧洲200名患者中减轻心房的负担的能力,预计结果将在2027年初公布. Acesion Pharma has started a Phase 2 trial for AP31969, an oral drug, testing its ability to reduce atrial fibrillation burden in 200 patients across Europe, with results expected by early 2027. 这两种药物都旨在为目前的治疗提供更安全的替代方法。 Both drugs aim to offer safer alternatives to current treatments.